|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Shibuya K, Mathers CD, Boschi-Pinto C,
Lopez AD and Murray CJ: Global and regional estimates of cancer
mortality and incidence by site: II. Results for the global burden
of disease 2000. BMC cancer. 2:372002. View Article : Google Scholar
|
|
3
|
DeWire SM and Violin JD: Biased ligands
for better cardiovascular drugs: dissecting G-protein-coupled
receptor pharmacology. Circ Res. 109:205–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hill SJ: G-protein-coupled receptors:
past, present and future. Br J Pharmacol. 147(Suppl 1): S27–S37.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berger A, Santic R, Almer D, et al:
Galanin and galanin receptors in human gliomas. Acta Neuropathol.
105:555–560. 2003.PubMed/NCBI
|
|
6
|
Berger A, Lang R, Moritz K, et al: Galanin
receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma
cells. Endocrinology. 145:500–507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wittau N, Grosse R, Kalkbrenner F, Gohla
A, Schultz G and Gudermann T: The galanin receptor type 2 initiates
multiple signaling pathways in small cell lung cancer cells by
coupling to G(q), G(i) and G(12) proteins. Oncogene. 19:4199–4209.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanazawa T, Iwashita T, Kommareddi P, et
al: Galanin and galanin receptor type 1 suppress proliferation in
squamous carcinoma cells: activation of the extracellular signal
regulated kinase pathway and induction of cyclin-dependent kinase
inhibitors. Oncogene. 26:5762–5771. 2007. View Article : Google Scholar
|
|
9
|
Seufferlein T and Rozengurt E: Galanin,
neurotensin, and phorbol esters rapidly stimulate activation of
mitogen-activated protein kinase in small cell lung cancer cells.
Cancer Res. 56:5758–5764. 1996.PubMed/NCBI
|
|
10
|
Iishi H, Tatsuta M, Baba M, et al:
Inhibition by galanin of experimental carcinogenesis induced by
azaserine in rat pancreas. Int J Cancer. 75:396–399. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Misawa Y, Misawa K, Kanazawa T, et al:
Tumor suppressor activity and inactivation of galanin receptor type
2 by aberrant promoter methylation in head and neck cancer. Cancer.
120:205–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanazawa T, Kommareddi PK, Iwashita T, et
al: Galanin receptor subtype 2 suppresses cell proliferation and
induces apoptosis in p53 mutant head and neck cancer cells. Clin
Cancer Res. 15:2222–2230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanazawa T, Misawa K and Carey TE: Galanin
receptor subtypes 1 and 2 as therapeutic targets in head and neck
squamous cell carcinoma. Expert Opin Ther Targets. 14:289–302.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Misawa K, Kanazawa T, Misawa Y, et al:
Galanin has tumor suppressor activity and is frequently inactivated
by aberrant promoter methylation in head and neck cancer. Transl
Oncol. 6:338–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Misawa K, Ueda Y, Kanazawa T, et al:
Epigenetic inactivation of galanin receptor 1 in head and neck
cancer. Clin Cancer Res. 14:7604–7613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henson BS, Neubig RR, Jang I, et al:
Galanin receptor 1 has anti-proliferative effects in oral squamous
cell carcinoma. J Biol Chem. 280:22564–22571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tofighi R, Joseph B, Xia S, et al: Galanin
decreases proliferation of PC12 cells and induces apoptosis via its
subtype 2 receptor (GalR2). Proc Natl Acad Sci USA. 105:2717–2722.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uehara T, Kanazawa T, Mizukami H, et al:
Novel anti-tumor mechanism of galanin receptor type 2 in head and
neck squamous cell carcinoma cells. Cancer Sci. Oct 30–2013.(Epub
ahead of print).
|
|
19
|
Lang R, Gundlach AL and Kofler B: The
galanin peptide family: receptor pharmacology, pleiotropic
biological actions, and implications in health and disease.
Pharmacol Ther. 115:177–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fathi Z, Cunningham AM, Iben LG, et al:
Cloning, pharmacological characterization and distribution of a
novel galanin receptor. Brain Res Mol Brain Bres. 51:49–59. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smith KE, Forray C, Walker MW, et al:
Expression cloning of a rat hypothalamic galanin receptor coupled
to phosphoinositide turnover. J Biol Chem. 272:24612–24616. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang S, Clemmons A, Strader C and Bayne M:
Evidence for hydrophobic interaction between galanin and the GalR1
galanin receptor and GalR1-mediated ligand internalization:
fluorescent probing with a fluorescein-galanin. Biochemistry.
37:9528–9535. 1998. View Article : Google Scholar
|
|
23
|
Fathi Z, Battaglino PM, Iben LG, et al:
Molecular characterization, pharmacological properties and
chromosomal localization of the human GALR2 galanin receptor. Brain
Res Mole Brain Res. 58:156–169. 1998. View Article : Google Scholar
|
|
24
|
Wang S, Hashemi T, He C, Strader C and
Bayne M: Molecular cloning and pharmacological characterization of
a new galanin receptor subtype. Mol Pharmacol. 52:337–343.
1997.PubMed/NCBI
|
|
25
|
Hagemeister AL, Kittilson JD, Bergan HE
and Sheridan MA: Rainbow trout somatostatin receptor subtypes
SSTR1A, SSTR1B, and SSTR2 differentially activate the extracellular
signal-regulated kinase and phosphatidylinositol 3-kinase signaling
pathways in transfected cells. J Mol Endocrinol. 45:317–327. 2010.
View Article : Google Scholar
|
|
26
|
War SA and Kumar U: Coexpression of human
somatostatin receptor-2 (SSTR2) and SSTR3 modulates
antiproliferative signaling and apoptosis. J Mol Signal. 7:52012.
View Article : Google Scholar : PubMed/NCBI
|
